Devin Brandt PhD
Address: Seattle *****, United States
Phone number: 206-***-****
Email address: ********@*****.***
Over ten years of pre-clinical experience in biophysical research and development across myriad disciplines. Analytical and assay development specialist focusing on creative solutions. Founder of Physalia Bioconsulting, which leverages PhD-organized AI clusters to assist in method and analytical development. Profile
Work Experience
01/2025 – present
Seattle, USA
Founder
Physalia Bioconsulting
Founder of Physalia Bioconsulting, a novel consulting company leveraging PhD- organized AI clusters to assist in method and analytical development. Manage and organize workflow of 5+ PhD-level scientists with the goal of rapidly responding to consulting requests.
Trained and optimized cluster of 5 low-independence AI agents to rapidly develop methods for RNA biophysical analysis.
03/2022 – 02/2025
Seattle, Washington, USA
Scientist
Access to Advanced Health Institute (AAHI)
Designed and tested new saRNA vaccine constructs for H5N1 influenza, Covid, TB and Chikungunya
Worked with the Formulation Group to ptimize various formulations of an existing H5N1 saRNA vaccine for nasal delivery. Chose single formulation from a pool of 20+ candidates
Established and validated 3 protocols for USP-validated assays for quantifying RNA integrity, capping efficiency and extent of polyadenylation. Used DoE to determine ideal conditions. Assisted in tech-transfer to QC/GMP group Set up 2 protocols for the biophysical characterization of highly heterogenous lipid- RNA complexes.
Oversaw 3 in vivo studies assaying the effect of various proprietary adjuvants on a saRNA/protein-based tuberculosis vaccine. Oversaw teams of 2-4 RA's during necropsy and organ processing.
Wrote reports and presented to external partners including FDA, DoD and NAIAD. Assited in decision making process for these reports and presentations. 09/2019 – 09/2021 Post Doctoral Researcher
UC Davis
Set up wet lab to study the extent of topological knotting in extracted phage DNA Trained multiple undergraduate students in various laboratory techniques, including PCR, gel electrophoresis, electron microscopy and proteomics. Set up workflow for the ab initio prediction of phage portal topology using combinatorial filtering of predicted quaternary structures. Generated first predicted structure of Phi29 portal structure. 05/2018 – 06/2019 Post Doctoral Researcher
UCLA
Designed novel, autocatalytic saRNAs to generate large amounts of miRNA in vivo Measured various biophysical parameters of novel saRNA Quantified the expression of saRNA as well as accumulation of miRNA in transfected cells.
Work Experience
Measured the effects of initial copy number on the duration and intensity of saRNA psuedoinfection in mammalian cells
Designed various assays to quantify RNA expression and miRNA release. Skills
Design of Experiment
(DoE) RNA biochemistry HPLC mRNA design
Protein Folding and
Design Lipid Nanotechnology Self-amplifying RNA Vaccine Design Protein Characterization Biostatistics Virology Cell Culture RT-qPCR/PCR/ddPCR
Next-generation
Sequencing Assay Design
Analytical Development
for QC Spaces
Molecular
Biology/Cloning AI Prompt Engineering Python Flow Cytometry ELISA ELISPOT Protein Purification FPLC
Pre-clinical Research Western Blot Technical Writing USP Techniques FDA Submissions Statistical Analysis RNA-seq Ligan-binding Assays Education
01/2011 – 01/2018 Biophysics Doctor of Philosophy University of California Los Angeles
01/2006 – 01/2010 Biochemistry Bachelor of Arts
University of Colorado Boulder
Publications
02/2022 The Nonmonotonic Dose Dependence of Protein Expression in Cells Transfected with Self-Amplifying RNA
Journal of Virology
https://pmc.ncbi.nlm.nih.gov/articles/PMC9006910/
Development of an Intranasally- and Intramuscularly-Administrable Self-Amplifying RNA Vaccine Efficacious Against H5N1 Influenza Journal of Controlled Release
In Review
A Spray Dried Self-Amplifying RNA Vaccine Platform for Pandemic Response
Journal of Controlled release
In Review